Bilateral ocular surface squamous neoplasia: A study of 25 patients and review of literature

Eur J Ophthalmol. 2022 Jan;32(1):620-627. doi: 10.1177/11206721211007109. Epub 2021 Apr 5.

Abstract

Purpose: To describe the risk factors, clinical presentation, management, and outcomes of patients with bilateral ocular surface squamous neoplasia (OSSN).

Methods: Retrospective case series.

Results: Of the 25 patients with bilateral OSSN, the mean age at diagnosis of OSSN was 31 years (median, 24 years; range, 2-60 years). Risk factors for bilateral OSSN included xeroderma pigmentosum (n = 15, 60%), human immunodeficiency virus infection (n = 3, 12%), conjunctival xerosis (n = 1, 4%), and topical steroid use (n = 1, 4%). There were no identifiable ocular or systemic risk factors in 7 (28%) patients. Presentation was synchronous in 14 (56%) and metachronous in 11 (44%) patients. Tumor morphology was bilaterally similar in 12 (48%) patients. Histopathological examination (n = 36) revealed conjunctival intraepithelial neoplasia (CIN) grade 1 in 4 (8%); grade 2 in 7 (14%); carcinoma in situ in 5 (10%), and invasive carcinoma in 20 (40%). Primary management of OSSN (n = 49) included excisional biopsy (n = 31, 62%), topical immunotherapy (IFN α2B) (n = 11; 22%), topical Mitomycin C (MMC) (n = 3, 6%), enucleation (n = 1, 2%), orbital exenteration (n = 2, 4%), and plaque brachytherapy (PBT) (n = 1, 2%). One patient was lost to follow-up after detection of tumor in the second eye. Recurrent tumors were noted in 16 (32%) eyes and binocular globe salvage was achieved in 16 (64%) patients at a mean follow up of 41 months (median 30 months; range, 1-164 months).

Conclusion: OSSN occurrence can be synchronous or metachronous. Meticulous examination of the fellow eye is important for an early diagnosis of OSSN.

Keywords: Eye; OSSN; bilateral OSSN; human immunodeficiency virus; ocular surface squamous neoplasia; tumor; xeroderma pigmentosum.

Publication types

  • Review

MeSH terms

  • Carcinoma in Situ* / therapy
  • Carcinoma, Squamous Cell* / therapy
  • Conjunctival Neoplasms* / therapy
  • Eye Neoplasms* / diagnosis
  • Eye Neoplasms* / therapy
  • Humans
  • Neoplasm Recurrence, Local
  • Retrospective Studies